Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Clinical trial NCT05052372 · TERMINATED

Trial details

NCT number: NCT05052372
Sponsor: xCures
Status: TERMINATED
Study type: OBSERVATIONAL

Bladder Cancer Urothelial Carcinoma Transitional Cell Carcinoma Platinum-Resistant Urothelial Carcinoma Bladder Urothelial Carcinoma FGFR Mutation FGFR2 Gene Mutation FGFR3 Gene Mutation FGFR2 Amplification Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Refractory Bladder Carcinoma

Start date: 2021-11-21
Primary completion: 2022-12-20
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.